PL3442535T3 - Związki heterocykliczne jako inhibitory kinazy ret - Google Patents

Związki heterocykliczne jako inhibitory kinazy ret

Info

Publication number
PL3442535T3
PL3442535T3 PL17719688.8T PL17719688T PL3442535T3 PL 3442535 T3 PL3442535 T3 PL 3442535T3 PL 17719688 T PL17719688 T PL 17719688T PL 3442535 T3 PL3442535 T3 PL 3442535T3
Authority
PL
Poland
Prior art keywords
kinase inhibitors
heterocyclic compounds
ret kinase
ret
heterocyclic
Prior art date
Application number
PL17719688.8T
Other languages
English (en)
Inventor
Allan Jordan
Rebecca NEWTON
Bohdan Waszkowycz
Jonathan Mark Sutton
George Hynd
Silvia PAOLETTA
Euan Alexander Fraser Fordyce
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of PL3442535T3 publication Critical patent/PL3442535T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
PL17719688.8T 2016-04-15 2017-04-18 Związki heterocykliczne jako inhibitory kinazy ret PL3442535T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606635 2016-04-15
PCT/GB2017/051077 WO2017178845A1 (en) 2016-04-15 2017-04-18 Heterocyclic compounds as ret kinase inhibitors

Publications (1)

Publication Number Publication Date
PL3442535T3 true PL3442535T3 (pl) 2022-10-24

Family

ID=58633036

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17719688.8T PL3442535T3 (pl) 2016-04-15 2017-04-18 Związki heterocykliczne jako inhibitory kinazy ret

Country Status (14)

Country Link
US (3) US10844067B2 (pl)
EP (2) EP3442535B1 (pl)
CY (1) CY1125551T1 (pl)
DK (1) DK3442535T3 (pl)
ES (1) ES2925698T3 (pl)
HR (1) HRP20221051T8 (pl)
HU (1) HUE060082T2 (pl)
LT (1) LT3442535T (pl)
PL (1) PL3442535T3 (pl)
PT (1) PT3442535T (pl)
RS (1) RS63609B1 (pl)
SI (1) SI3442535T1 (pl)
SM (1) SMT202200348T1 (pl)
WO (1) WO2017178845A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
WO2017178844A1 (en) 2016-04-15 2017-10-19 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
SI3442535T1 (sl) 2016-04-15 2023-01-31 Cancer Research Technology Limited Heterociklične spojine kot zaviralci RET-kinaze
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物
EP3740490A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
PE20210096A1 (es) 2018-04-03 2021-01-12 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
KR20230104781A (ko) 2020-10-05 2023-07-10 인라이븐 테라퓨틱스, 인크. Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322779A3 (en) 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
US6783672B2 (en) * 2001-01-18 2004-08-31 Kemmons A. Tubbs Integrated high throughput system for the mass spectrometry of biomolecules
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
ES2365869T3 (es) 2005-11-17 2011-10-11 OSI Pharmaceuticals, LLC COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
ES2545907T3 (es) 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd 1−ピリジン−4−イル−インドール類の製造方法
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US20090274698A1 (en) 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
NZ599830A (en) 2009-11-05 2014-08-29 Rhizen Pharmaceuticals Sa Novel kinase modulators
EP2528919B1 (en) 2010-01-28 2016-11-02 University of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20130296316A1 (en) 2010-07-09 2013-11-07 Michael P. Pollastri Antiparasitic Agents Based On mTOR Inhibitors
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
JP6047149B2 (ja) 2011-05-04 2016-12-21 インテリカイン, エルエルシー 併用の医薬組成物およびその使用
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
WO2013070976A1 (en) 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン, エルエルシー Mtor阻害剤を使用する強化された治療レジメン
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US8889730B2 (en) * 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CA2922044A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
CA2922058A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
GB201321146D0 (en) * 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
KR102562866B1 (ko) 2014-11-14 2023-08-04 네르비아노 메디칼 사이언시스 에스.알.엘. 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
CA2974702C (en) 2015-01-26 2023-10-10 University Of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
WO2017160717A2 (en) 2016-03-15 2017-09-21 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
SI3442535T1 (sl) 2016-04-15 2023-01-31 Cancer Research Technology Limited Heterociklične spojine kot zaviralci RET-kinaze
WO2017178844A1 (en) 2016-04-15 2017-10-19 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors

Also Published As

Publication number Publication date
RS63609B1 (sr) 2022-10-31
SMT202200348T1 (it) 2022-11-18
CY1125551T1 (el) 2026-02-25
US11661423B2 (en) 2023-05-30
US20240116938A1 (en) 2024-04-11
EP3442535A1 (en) 2019-02-20
EP3442535B1 (en) 2022-06-01
DK3442535T3 (da) 2022-09-05
US10844067B2 (en) 2020-11-24
EP4104837A2 (en) 2022-12-21
HRP20221051T8 (hr) 2023-07-21
LT3442535T (lt) 2022-10-25
ES2925698T3 (es) 2022-10-19
PT3442535T (pt) 2022-09-05
US20210047334A1 (en) 2021-02-18
HUE060082T2 (hu) 2023-01-28
US20190263819A1 (en) 2019-08-29
HRP20221051T1 (hr) 2023-03-03
SI3442535T1 (sl) 2023-01-31
EP4104837A3 (en) 2023-04-26
WO2017178845A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
CY1125551T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις της κινασης ret
CY2024003I2 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
IL289793A (en) Heterocyclic compounds as ret kinase inhibitors
IL276509A (en) Heterocyclic compounds as kinase inhibitors
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
CY1125896T1 (el) Ενωσεις χρησιμες ως αναστολεις ret
LT3710446T (lt) Junginiai, naudingi cdk7 slopinimui
IL259406B (en) Heterocyclic compounds as immunomodulators
LT3472167T (lt) Heterocikliniai junginiai kaip imunomoduliatoriai
PL3209656T3 (pl) Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy
HUE042390T2 (hu) Heteroaril vegyületek kinázgátlásra
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3436444T3 (da) Heterocyklisk forbindelse
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
DK3498693T3 (da) Heterocyklisk forbindelse
DK3724190T3 (da) Substituerede bicykliske heterocykliske forbindelser som PRMT5 inhibitorer
EP3152210C0 (en) TANK-BINDING KINASE INHIBITORY COMPOUNDS
PL3224256T3 (pl) Związki n-((het)arylometylo-heteroarylo-karboksyamidowe jako inhibitory kalikreiny osoczowej
IL255750A (en) Heterocyclic compounds as kinase inhibitors
IL266789A (en) Heterocyclic compounds as kinase inhibitors
EP3849985A4 (en) ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS
MA44607A (fr) Inhibiteurs de kinase
AU2024203236A1 (en) Heterocyclic compounds as RET kinase inhibitors
HK1260208A1 (en) Heterocyclic compounds as ret kinase inhibitors